NASDAQ · LPTX
Healthcare · Biotechnology
$0.77
Down-$0.03 (-3.15%)
Updated Oct 7, 2026, 1:19 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LPTX
1M range · 0 trading sessions · Daily adjusted prices
LPTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning LPTX.
Company
Market Activity
Research & News
LPTX research
Company profile and research snapshot.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2025 | HC Wainwright & Co. | Neutral | — |
| Jan 29, 2025 | HC Wainwright & Co. | Neutral | — |
| Jan 16, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
prnewswire.com · Nov 12, 2025
CAMBRIDGE, Mass. , Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash, today reported financial results for the third quarter of 2025 and a corporate update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LPTX.
No results
No recent SID articles mention LPTX.
